Skip to main content
. Author manuscript; available in PMC: 2015 Jun 15.
Published in final edited form as: Cancer. 2014 Mar 13;120(12):1780–1786. doi: 10.1002/cncr.28648

Figure 1.

Figure 1

Using multivariable analysis adjusted for known clinical prognostic factors and receipt of bevacizumab, baseline serum albumin (b-alb) remained a significant independent predictor of (Top) overall survival (OS) (P =.0009) and (Bottom) time to disease progression (TTP) (P =.04). ULN indicates upper limit of normal; ECOG PS, Eastern Cooperative Oncology Group performance status; HR, hazards ratio; 95% CI, 95% confidence interval.